The company said it has sufficient financial resources to fund its operations into early 2027.Biotech Nektar Therapeutics (NKTR 5.70%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet resultsIn its second quarter, Nektar booked total revenue of just under $11 ...